In patients with RCC, exceptional response to immunotherapy may be related to clonal neoantigen-driven cytotoxic T-cell ...

This SPA agreement marks an important milestone in the development of Descartes-08 for MG, providing critical regulatory clarity and a clear path toward potential approval,” said Carsten Brunn, Ph.D., ...

Enhances B Cell Responses in Type 2 Inflammation Through IL-17RB Receptor,” published in the January 2025 issue of Allergy ...

BV + Len + R may be considered as a bridging therapy for patients with R/R DLBCL prior to chimeric antigen receptor-T or other more definitive ... v negative [<1%]), cell of origin (germinal center B ...

Interferons activate or upregulate immune cells by interacting with receptors that activate signal transducer and activator of transcription (STAT) signalling complexes. This ultimately leads to ...

A new experimental vaccine could offer protection not only against many variants of SARS-CoV-2, but also other sarbecoviruses that could spill over from animals to humans.

T-cell therapy, originally developed for haematological malignancies, has recently emerged as a promising therapy for ...

A group of immune proteins called the inflammasome can help prevent blood stem cells from becoming malignant by removing certain receptors from their surfaces and blocking cancer gene activity, ...

Dark zone lymphoma includes aggressive B-cell lymphomas with shared molecular features. While some respond to escalated ...

1Center of Translational and Molecular Medicine, UMR1231, Inserm-Université de Bourgogne, Dijon, France. *Corresponding Author: Ronan Quéré, INSERM U1231, Center of Translational and Molecular ...

1 Despite several treatment options, including approved thrombopoietin receptor agonists and commonly used antibody-reducing approaches—such as B-cell depletion with the anti-CD20 monoclonal antibody ...